Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. Queensland was the source of 51% of prescriptions between 2016 and 2021.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Peninsula Alternative Health

MARCH 1, 2018

Check out this comprehensive list by Peninsula Alternative Health in Salisbury, Maryland: Americans for Safe Access (ASA). based nonprofit and Americans for Safe Access Foundation “share the mission of ensuring safe and legal access to cannabis.for therapeutic use and research,” according to its website. This Washington, D.C.-based

Treatment 40

Treatment Education Advocacy Access 40

Peninsula Alternative Health

MARCH 1, 2018

Check out this comprehensive list by Peninsula Alternative Health in Salisbury, Maryland: Americans for Safe Access (ASA). based nonprofit and Americans for Safe Access Foundation “share the mission of ensuring safe and legal access to cannabis.for therapeutic use and research,” according to its website. This Washington, D.C.-based

Treatment 40

Treatment Education Advocacy Access 40

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Medicinal cannabis as a last resort.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. Research published in 2016 revealed that 59% of a sample of patients who misused opioids were first exposed to them through a medical prescription.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

MARCH 17, 2022

The national consumption of methylamphetamine, cocaine, MDMA and heroin increased year on year in the first four years of the Program (2016-17 to 2019-20), followed by a marked reduction in total consumption in year five (2020-21). The latest report presents data on Australia’s drug consumption for 12 substances. million Australians.

Consumption 52

Consumption Programs Data Treatment 52

Healer

MARCH 26, 2021

Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. They’re an effective treatment for pain, but they’re not great for chronic pain, and many people are reluctant to start on opioids,” he said.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. In November of 2016, 71% of Florida voters approved the Florida Medical Marijuana Legalization Initiative (perhaps confusingly: also known as Amendment 2 ). .’

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JUNE 8, 2022

Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. MDMA-assisted therapy, a novel treatment for PTSD with FDA breakthrough therapy designation, is on track for NDA submission in 2023 pending results of the confirmatory Phase 3 trial. Published: Jun 07, 2022. He holds a Ph.D.

Therapy 52

Therapy Treatment Access Patients 52

PrestoDoctor

SEPTEMBER 6, 2023

One of the primary reasons for this shift is the growing acceptance and accessibility of cannabis as an alternative pain management option. In regions where medical cannabis is accessible, some studies have shown a decrease in opioid prescriptions and opioid-related fatalities.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

NOVEMBER 14, 2019

Australia’s westernmost state is making it easier for patients to access medical cannabis. When considering many using medicinal cannabis products have serious illnesses and are sometimes financially strained, the previous access regime unnecessarily added a number of months and additional costs to the process.”

Patients 45

Patients Access Medicine Pharmaceutical 45

CannaMD

NOVEMBER 6, 2019

As more people gain access to medical marijuana, dependence on opioids for pain relief is likely to decline. The authors state: We find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 6.9 Many patients preferred cannabis over opioids. percent, respectively.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Schedule I controlled substances are the most restricted in terms of research, supply, and access, [13] and possession is criminalized.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 26, 2019

Minister for Health Simon Harris TD today signed legislation which will allow for the operation of the Medical Cannabis Access Programme on a pilot basis for five years. The Programme will facilitate access to cannabis-based products for medical use in line with legislation. We have highlighted relevant passages.

Medicine 55

Medicine Access Business Legislation 55

Cannabis Law Report

JANUARY 9, 2022

Oregon voters approved an initiative regulating cannabis for adult use in November 2014, and the state’s first adult-use stores opened in October 2016. In addition, the legislature allowed medical cannabis dispensaries to sell a limited amount of cannabis (five grams) to adults from October 2015 until December 31, 2016. 46,104,922.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

FEBRUARY 17, 2020

The Committee will convene telephonically and in-person bimonthly to develop ways and methods to expand patient access and affordability, increase innovation and technology within the cannabis industry, and to make recommendations to the Legislature and the Department of Health’s Office of Medical Marijuana Use (OMMU). CANNABIS PRIMER.

Dispensary 76

Dispensary Patients Agriculture Conditions 76

Cannabis Law Report

JULY 24, 2022

The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years [1]. The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 billion by 2029.

Research and Development 52

Research and Development Legalization Treatment Patients 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Le-Short C.,

Patients 98

Patients Education Marijuana Therapy 98

Sensi Seeds

JANUARY 4, 2019

Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). It allows patients to have access to medicinal cannabis without danger of being criminalized. Context of the Medicinal Cannabis Situation.

Medicine 75

Medicine Research and Development Patients Programs 75

NORML

MAY 24, 2019

At the same time, the bill would redirect tax revenue from a legal industry towards various programs that redress harms from the War on Drugs, while also increasing and improving public education and treatment programs geared towards responsible use, reducing overdoses, and saving lives. percent in 2016. times more likely.

Marijuana 103

Marijuana Education Advocacy Legislation 103

Cannabis Law Report

DECEMBER 21, 2021

According to Fundera, these industries anticipate 115 – 121% job growth over ten years (2016-2026). Healthcare – Biotechnology, data management, and personalized health are primary growth factors of the healthcare industry, Fundera’s research reveals. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Veriheal

OCTOBER 5, 2020

According to data from another American state, Colorado, cannabis edibles account for as much as 45% of all cannabis sales – which excludes those home-made edibles made from bought or grown cannabis bud (the flower we consume). The bill allows for eight dispensaries in the state, each of which has been designated by the islands. .

Edibles 52

Edibles Legalization Decriminalization Consumption 52

Cannabis Law Report

JULY 30, 2019

For now, both Florida’s restrictions and federal restrictions on the scheduling of cannabis still apply as states scramble to formulate respective regulations for research, access, education, innovation. There is a distinct lack of past aggregated credible, published, accessible ongoing research or case studies.

Marijuana 40

Marijuana Education Patients Research and Development 40

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60

SpeedWeed

MARCH 6, 2021

Florida for Care Executive Director Ben Pollara, the legalization advocate who helped lead Florida’s successful medical marijuana campaign in 2016, pointed out another problem in a recent op-ed published in the Fort Myers News-Press. In legal US states, access to cannabis has been limited to those 21 and older in adult-use markets.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

SEPTEMBER 27, 2021

New York, with approximately 15 million residents over the age of 21, first launched its medical cannabis program in 2016, which has generally been considered restrictive, with fewer qualifying medical conditions and other restrictions which have inhibited growth of the regulated medical cannabis market in the fourth largest state by population.

Programs 52

Programs Patients Cultivation Dispensary 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

AUGUST 23, 2021

Medicinal Cannabis Access Data Dashboard. To improve transparency and data accessibility, the TGA publishes de-identified data on the number of unapproved medicinal cannabis products accessed through the Special Access Scheme (SAS). Medicinal cannabis Special Access Scheme category B data.

Data 105

Data Access Medicine Patients 105

The Cannigma

JANUARY 13, 2023

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” Daily cannabis consumption was an effective treatment for 85% of participants. This system shows up in several studies. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.

Research and Development 52

Research and Development Medicine Access Media 52

Medicinal Genomics

MARCH 10, 2020

2016; McKernan 2018). coli in the 42 x g pellet with and without a nuclease treatment. The growers lobby for the test they can counterfeit with microwave or other sterilization treatments as they fear PCR will penalize them for dead DNA. 2015; McKernan et al. Quantitative PCR (qPCR) assay detecting E. coli and hemp. Conclusions.

Trichome 107

Trichome Data Digestion Patients 107

The Cannigma

JUNE 29, 2021

Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using. It could also help healthcare professionals make better decisions when recommending cannabis treatment, and help consumers get the most out of their cannabis experience.

Terpenes 138

Terpenes Research and Development Cannabinoids Concentrates 138

Cannabis Law Report

JANUARY 10, 2020

xi The marijuana industry experienced substantial growth in recreational sales through mid-2017, with sales doubling twice between 2014 and 2016 (Chart 2). Medical sales peaked toward the end of 2016, while recreational sales continued to rise. percent compared with the previous year. Conclusion.

Banking 59

Banking Marijuana Collective Recreational 59

SpeedWeed

JULY 19, 2021

On June 23, Canada’s cannabis regulatory agency, Health Canada, released a private document requested under the Access to Information Act (AIA), that country’s version of the US government’s Freedom of Information Act. The data contained in that report has rocked the cannabis vaping world. The data was far worse than he imagined.

Vaping 52

Vaping Terpenes Data Research and Development 52

CannaMD

MAY 14, 2020

Florida’s medical marijuana community may soon have access to edible forms of cannabis. CannaMD has contacted Florida’s leading medical marijuana treatment centers (MMTCs) , who say they’re now just waiting on the Department of Health to issue rules regarding packaging and other essential requirements.

Edibles 105

Edibles Marijuana THC Vaping 105

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. iv Named-patient and compassionate use proceduresThe TG Act provides mechanisms that allow individuals to gain limited access to UTGs (defined in Section II.iii). The institution at which the trial will be conducted gives the final approval.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52